Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400712 | 1.00 | TDP1 (0.48) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL9931542 | 1.00 | TDP1 (0.48) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL12604209 | 0.97 | MEN1 (0.48) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL30895563 | 0.97 | MEN1 (0.48) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL18206801 | 0.94 | CA1 (0.49) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL18206800 | 0.94 | CA1 (0.49) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL15893373 | 0.93 | TDP1 (0.44) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL18978546 | 0.91 | TDP1 (0.42) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL15698479 | 0.91 | KLK7 (0.40) | TDP1ATMPOLBNPSR1MEN1 | |
| SCHEMBL21901505 | 0.91 | MEN1 (0.44) | TDP1ATMPOLBNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| EP-4619037-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| US-20250255973-A1 | HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS | ASCENDIS PHARMA GMBH (DE) | 2025-08-14 | — | — | US | disclosed |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12325688-B2 | Gingerenone A prodrugs as sensotherapeutics and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-10 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250129064-A1 | PRODRUGS OF 2-BROMO-LSD (2-BROMOLYSERGIC ACID DIETHYLAMIDE) | TERRAN BIOSCIENCES INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2009015811-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | WO | disclosed |
| US-7375083-B2 | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080086016-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008022786-A1 | AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-7223735-B2 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
| EP-0215805-A1 | IMMUNOREGULATORY PEPTIDES | MERCK PATENT GmbH (DE) | 1987-04-01 | — | — | EP | disclosed |
| WO-1986004334-A1 | IMMUNOREGULATORY PEPTIDES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325688-B2 | Gingerenone A prodrugs as sensotherapeutics and methods of use | AGER, RGS16, GRIA2 | TDP1 2343/4885ATM 1657/4885POLB 4449/4885 |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | TDP1 2600/4885ATM 4801/4885POLB 2401/4885 |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | COMT, CYP3A5, CYP2D6 | TDP1 142/4885ATM 2021/4885POLB 2012/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | TDP1 1693/4885ATM 4264/4885POLB 1642/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | TDP1 2633/4885ATM 4711/4885POLB 3888/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | TDP1 678/4885ATM 3655/4885POLB 3020/4885 |
| US-20250255973-A1 | HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS | CD44, HCAR3, HPSE | TDP1 1956/4885ATM 3070/4885POLB 4443/4885 |
| US-20250129064-A1 | PRODRUGS OF 2-BROMO-LSD (2-BROMOLYSERGIC ACID DIETHYLAMIDE) | GBA2, GBA1, SLC18A2 | TDP1 521/4885ATM 3890/4885POLB 2645/4885 |
| US-20080086016-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | COMT, KDM6B, KDM5B | TDP1 339/4885ATM 1108/4885POLB 2281/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | TDP1 1278/4885ATM 3889/4885POLB 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.